Quarterly ResultAug 5, 2026, 04:15 PM

Zomedica Q2 Revenue +36.5% to $9.51M; Net Loss Narrows

AI Summary

Zomedica Corp. reported a substantial increase in net revenue for the second quarter and first half of 2026, driven by strong growth across its Diagnostics and Therapeutic Devices segments, and the emergence of Development Services revenue. The company also significantly reduced its net loss compared to the prior year, primarily due to the absence of a large impairment charge recorded in 2025. Despite the revenue growth, cash and total assets decreased from year-end 2025.

Key Highlights

Q2 2026 net revenue increased 36.5% to $9.51 million.
Six-month 2026 net revenue grew 36.0% to $18.31 million.
Q2 2026 net loss narrowed to $(3.77) million from $(7.40) million.
Six-month 2026 net loss reduced to $(8.30) million from $(71.21) million.
Diagnostics segment revenue surged 77.3% to $1.39 million in Q2 2026.
Therapeutic Devices segment revenue rose 9.2% to $6.75 million in Q2 2026.
Development Services generated $1.37 million in Q2 2026 revenue.
Cash and cash equivalents decreased to $7.19 million from $9.02 million at year-end 2025.

View SEC Filing

ZOMDF

Pharmaceutical Preparations

Zomedica Corp.

Price Impact